CNS & Neurological Disorders - Drug Targets
Title:Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017
Volume: 16 Issue: 10
Author(s): Hari S. Sharma*, Stephen D. Skaper and Aruna Sharma
Affiliation:
- International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Biology, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, SE-75185 Uppsala,Sweden
Export Options
About this article
Cite this article as:
Sharma S. Hari*, Skaper D. Stephen and Sharma Aruna , Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/187152731610180313114311
DOI https://dx.doi.org/10.2174/187152731610180313114311 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: G-Protein-Coupled Receptors (GPCRs) and Drug Discovery (Guest Editor: Luca Gentilucci)]
Current Drug Targets Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Neurotoxicity of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Gene and Cell Therapy for Prion Diseases
Infectious Disorders - Drug Targets Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study
Current Alzheimer Research Advent of Proteomic Tools for Diagnostic Biomarker Analysis in Alzheimer’s Disease
Current Protein & Peptide Science Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research